Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas
Open Access
- 28 June 2010
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 333
Abstract
Background: Serum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients compared to healthy donors, suggesting its potential utility for early diagnosis. Therefore we aimed to estimate the utility of the sCD26 as a biomarker for CRC and advanced adenomas in a high-risk group of patients. The relationship of this molecule with polyp characteristics was also addressed. Methods: sCD26 levels were measured by ELISA in 299 symptomatic and asymptomatic patients who had undergone a colonoscopy. Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC. Results: At a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% (95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology. Clinicopathological analysis of polyps showed a relationship between the sCD26 and the grade of dysplasia and the presence of advanced adenomas. Hence, a 58.0% (95% CI, 46.5-68.9%) sensitivity detecting CRC and advanced adenomas was obtained, with a specificity of 75.5% (95% CI, 68.5-81.0%). Conclusions: Our preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening of CRC and advanced adenomas. Additional comparative studies in average-risk populations are necessary.Keywords
This publication has 34 references indexed in Scilit:
- Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?Alimentary Pharmacology & Therapeutics, 2010
- A new multitest correction (SGoF) that increases its statistical power when increasing the number of testsBMC Bioinformatics, 2009
- Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of RadiologyGastroenterology, 2008
- Cancer Screening in the United States, 2008: A Review of Current American Cancer Society Guidelines and Cancer Screening IssuesCA: A Cancer Journal for Clinicians, 2008
- Colorectal cancer and dysplasia in inflammatory bowel diseaseWorld Journal of Gastroenterology, 2008
- Colorectal cancer screening: A comparison of 35 initiatives in 17 countriesInternational Journal of Cancer, 2007
- Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance CharacteristicsJNCI: Journal of the National Cancer Institute, 2007
- Polyp Miss Rate Determined by Tandem Colonoscopy: A Systematic ReviewAmerican Journal of Gastroenterology, 2006
- The multifunctional or moonlighting protein CD26/DPPIVEuropean Journal of Cell Biology, 2003
- Randomised controlled trial of faecal-occult-blood screening for colorectal cancerThe Lancet, 1996